X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3133) 3133
Newspaper Article (49) 49
Newsletter (40) 40
Magazine Article (14) 14
Book Chapter (7) 7
Dissertation (2) 2
Transcript (2) 2
Book / eBook (1) 1
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2590) 2590
hydroxychloroquine - therapeutic use (1804) 1804
hydroxychloroquine (1736) 1736
female (1578) 1578
male (1122) 1122
adult (1020) 1020
middle aged (931) 931
rheumatology (899) 899
antirheumatic agents - therapeutic use (751) 751
arthritis, rheumatoid - drug therapy (574) 574
treatment outcome (540) 540
lupus erythematosus, systemic - drug therapy (507) 507
aged (493) 493
systemic lupus erythematosus (470) 470
drug therapy, combination (449) 449
chloroquine (418) 418
lupus (395) 395
rheumatoid arthritis (383) 383
hydroxychloroquine - adverse effects (337) 337
methotrexate - therapeutic use (326) 326
methotrexate (308) 308
adolescent (272) 272
therapy (268) 268
dermatology (259) 259
immunosuppressive agents - therapeutic use (254) 254
patients (240) 240
antimalarials - therapeutic use (239) 239
hydroxychloroquine - administration & dosage (239) 239
risk factors (236) 236
disease (230) 230
rheumatoid-arthritis (225) 225
medicine, general & internal (224) 224
lupus erythematosus, systemic - complications (222) 222
retrospective studies (222) 222
chloroquine - therapeutic use (215) 215
care and treatment (214) 214
drug therapy (214) 214
animals (205) 205
pregnancy (204) 204
arthritis (195) 195
antirheumatic agents - adverse effects (194) 194
young adult (193) 193
glucocorticoids - therapeutic use (192) 192
prednisone - therapeutic use (182) 182
double-blind (181) 181
covid-19 (177) 177
sulfasalazine - therapeutic use (177) 177
health aspects (176) 176
severity of illness index (175) 175
autophagy (174) 174
follow-up studies (173) 173
pharmacology & pharmacy (173) 173
medicine & public health (172) 172
child (170) 170
immunology (166) 166
anti-inflammatory agents - therapeutic use (165) 165
time factors (163) 163
systemic-lupus-erythematosus (158) 158
clinical trials (157) 157
research (157) 157
abridged index medicus (156) 156
analysis (152) 152
diagnosis (150) 150
coronaviruses (149) 149
adrenal cortex hormones - therapeutic use (148) 148
hydroxychloroquine - pharmacology (144) 144
sulfasalazine (142) 142
diagnosis, differential (133) 133
drugs (130) 130
anti-inflammatory agents, non-steroidal - therapeutic use (129) 129
antimalarials (128) 128
cancer (124) 124
risk (124) 124
biopsy (122) 122
efficacy (120) 120
inflammation (120) 120
lupus erythematosus, systemic - diagnosis (117) 117
classification (114) 114
prednisolone - therapeutic use (114) 114
corticosteroids (113) 113
pandemics (113) 113
inhibition (112) 112
prospective studies (110) 110
medical research (108) 108
azathioprine - therapeutic use (107) 107
autoimmune diseases (106) 106
clinical trials as topic (106) 106
double-blind method (106) 106
mortality (106) 106
disease-activity (104) 104
aged, 80 and over (101) 101
dose-response relationship, drug (101) 101
prognosis (101) 101
cohort studies (100) 100
toxicity (100) 100
mice (99) 99
azathioprine (98) 98
antirheumatic agents - administration & dosage (97) 97
chloroquine - adverse effects (96) 96
disease progression (96) 96
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3002) 3002
French (118) 118
German (43) 43
Spanish (30) 30
Italian (17) 17
Chinese (9) 9
Portuguese (7) 7
Russian (7) 7
Polish (6) 6
Finnish (5) 5
Danish (4) 4
Dutch (3) 3
Romanian (3) 3
Hungarian (2) 2
Japanese (2) 2
Norwegian (2) 2
Breton (1) 1
Czech (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Medical Clinics of North America, ISSN 0025-7125, 05/2012, Volume 96, Issue 3, pp. 475 - 496
Over the past several decades, rheumatology has directed its focus to understanding and countering the immune dysregulation underlying autoimmune diseases with... 
Biologic response modifiers | Systemic lupus erythematosus | Vasculitis | Disease-modifying antirheumatic drugs | Biologics | Rheumatoid arthritis | SYSTEMIC-LUPUS-ERYTHEMATOSUS | RITUXIMAB THERAPY | 5-AMINOSALICYLIC ACID | REFRACTORY NEUROSARCOIDOSIS | ADENOSINE RECEPTORS | MEDICINE, GENERAL & INTERNAL | TUMOR-NECROSIS-FACTOR | COMBINATION TREATMENT | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | MYCOPHENOLATE-MOFETIL | Hydroxychloroquine - therapeutic use | Azathioprine - therapeutic use | Glucocorticoids - therapeutic use | Certolizumab Pegol | Rheumatic Diseases - drug therapy | Colchicine - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Immunoglobulin Fab Fragments - therapeutic use | Methotrexate - therapeutic use | Polyethylene Glycols - therapeutic use | Cyclophosphamide - therapeutic use | Receptors, Tumor Necrosis Factor - therapeutic use | Abatacept | Etanercept | Infliximab | Minocycline - therapeutic use | Immunoconjugates - therapeutic use | Antirheumatic Agents - therapeutic use | Rheumatic Diseases - immunology | Sulfasalazine - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Immunoglobulin G - therapeutic use | Rituximab | Cyclosporine - therapeutic use | Interleukin 1 Receptor Antagonist Protein - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Isoxazoles - therapeutic use | Adalimumab | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Tumor Necrosis Factors - antagonists & inhibitors
Journal Article
Cochrane library, ISSN 1469-493X, 05/2017, Volume 2017, Issue 5, pp. CD002954 - CD002954
Background Discoid lupus erythematosus (DLE) is a chronic form of cutaneous lupus, which can cause scarring. Many drugs have been used to treat this disease... 
antimalarial therapy | M. CONNECTIVE TISSUE AND IMMUNOBULLOUS AND RELATED | photoprotection | Treatment Outcome | Hydrocortisone | topical and intralesional (injected) corticosteroids | Dermatologic Agents | Skin disorders | Randomized Controlled Trials as Topic | Calcineurin Inhibitors | Fluocinonide | Connective tissue disorders & immunobullous | Acitretin | Hydroxychloroquine | Lupus Erythematosus, Discoid | Tacrolimus | thalidomide | M0 Lupus erythematosus | Lupus erythematosus | Albuterol | Medicine General & Introductory Medical Sciences | systemic corticosteroids | CUTANEOUS LUPUS | MULTICENTER | EFFICACY | SAFETY | Humans | Acitretin [therapeutic use] | Lupus Erythematosus, Discoid [drug therapy] | DISEASE AREA | THALIDOMIDE | CHLOROQUINE | Fluocinonide [therapeutic use] | MEDICINE, GENERAL & INTERNAL | Hydroxychloroquine [therapeutic use] | DOUBLE-BLIND | TOPICAL CALCINEURIN INHIBITORS | TACROLIMUS | Dermatologic Agents [therapeutic use] | Hydrocortisone [therapeutic use] | Hydroxychloroquine - therapeutic use | Fluocinonide - therapeutic use | Lupus Erythematosus, Discoid - drug therapy | Hydrocortisone - therapeutic use | Dermatologic Agents - therapeutic use | Tacrolimus - analogs & derivatives | Dermatologic Agents - adverse effects | Tacrolimus - therapeutic use | Calcineurin Inhibitors - therapeutic use | Albuterol - therapeutic use | Acitretin - therapeutic use | Acitretin - adverse effects | Index Medicus
Journal Article
European heart journal, ISSN 1522-9645, 2014, Volume 35, Issue 27, pp. 1782 - 1791
Atherothrombosis is no longer considered solely a disorder of lipoprotein accumulation in the arterial wall. Rather, the initiation and progression of... 
Darapladib | Atherosclerosis | Inflammasome | Inflammation | Colchicine | Salsalate | C reactive protein | Canakinumab | Methotrexate | Interleukin-6 | C-REACTIVE PROTEIN | FUTURE MYOCARDIAL-INFARCTION | CARDIAC & CARDIOVASCULAR SYSTEMS | INTERLEUKIN-1 RECEPTOR ANTAGONIST | RANDOMIZED CLINICAL-TRIAL | SECRETORY PHOSPHOLIPASE A | ACUTE CORONARY SYNDROME | APPARENTLY HEALTHY-MEN | REVERSE CHOLESTEROL TRANSPORT | PLACEBO-CONTROLLED TRIAL | TYPE-2 DIABETES-MELLITUS | Hydroxychloroquine - therapeutic use | Interleukin-6 - antagonists & inhibitors | NLR Family, Pyrin Domain-Containing 3 Protein | Colchicine - therapeutic use | Humans | Cell Adhesion Molecules - antagonists & inhibitors | Methotrexate - therapeutic use | Sirtuins - therapeutic use | Vaccination - methods | Lipoproteins, HDL - drug effects | Interleukin-1 - physiology | Interleukin-6 - physiology | Anti-Inflammatory Agents - therapeutic use | Interleukin-1 - antagonists & inhibitors | Leukotriene Antagonists - therapeutic use | Carrier Proteins - physiology | Adaptive Immunity - physiology | Phospholipase A2 Inhibitors - therapeutic use | Atherosclerosis - drug therapy | Serpins - therapeutic use | C-Reactive Protein - physiology | Antioxidants - therapeutic use | Tumor Necrosis Factor-alpha - drug effects | Signal Transduction - drug effects | Tumor Necrosis Factor-alpha - physiology | Thrombosis - drug therapy | Receptors, Interleukin-1 - antagonists & inhibitors | Review
Journal Article
BMJ Open, ISSN 2044-6055, 01/2017, Volume 7, Issue 1, p. e014032
... and severe HZ. The use of long-term medical records: a 14-year follow-up period (2001–2014) enhanced the statistical power and accuracy of this study. The present study... 
INFECTIONS | VIRUS | immunosuppressive medications | herpes zoster (HZ) | rheumatoid arthritis (RA) | risk factor | MEDICINE, GENERAL & INTERNAL | outcomes | VARICELLA | COMPLICATIONS | COHORT | NECROSIS FACTOR THERAPY | ANTAGONISTS | ASSOCIATION | BRITISH SOCIETY | EPIDEMIOLOGY | Hydroxychloroquine - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Herpes Zoster Ophthalmicus - epidemiology | Leflunomide | Methotrexate - therapeutic use | Adrenal Cortex Hormones - therapeutic use | Case-Control Studies | Young Adult | Rituximab - therapeutic use | Time Factors | Arthritis, Rheumatoid - drug therapy | Adult | Female | Herpes Zoster - epidemiology | Odds Ratio | Antirheumatic Agents - therapeutic use | Biological Products - therapeutic use | Severity of Illness Index | Sulfasalazine - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Risk Factors | Adalimumab - therapeutic use | Abatacept - therapeutic use | Taiwan - epidemiology | Aged | Isoxazoles - therapeutic use | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Etanercept - therapeutic use | Drugs | Codes | Biological products | Bacterial infections | Comorbidity | Rheumatology | Medical records | Infections | Epidemiology | Patients | Studies | Databases | Rheumatoid arthritis | Older people | Human immunodeficiency virus--HIV | Population | TNF inhibitors | Tumor necrosis factor-TNF | Health risk assessment | Viral infections
Journal Article
Journal Article
Arthritis & rheumatology (Hoboken, N.J.), ISSN 2326-5191, 2018, Volume 70, Issue 5, pp. 785 - 793
Journal Article